What is Rapid Novor?
Rapid Novor operates as a Contract Research Organization (CRO) dedicated to specialized antibody characterization and discovery. Leveraging advanced mass spectrometry techniques, the company provides critical services such as antibody sequencing, epitope mapping, and drug antibody ratio analysis. These offerings are instrumental for clients in the biotech and pharmaceutical industries, supporting the development of novel therapeutics and diagnostics. Rapid Novor's innovative solutions aim to accelerate drug discovery pipelines and enhance the understanding of antibody-based applications, including in vitro diagnostics, gene therapy, and biosimilar development.
How much funding has Rapid Novor raised?
Rapid Novor has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2020): $5M with participation from Co-Win Venture
Key Investors in Rapid Novor
Co-Win Venture
Co-Win Venture is an investor participating in the Series A funding round for Rapid Novor, indicating a focus on early-stage biotechnology or life sciences companies.
What's next for Rapid Novor?
The recent major strategic investment positions Rapid Novor for accelerated growth and expanded service offerings. This capital infusion is expected to fuel further technological advancements in mass spectrometry applications for antibody analysis and potentially broaden the company's market reach within the global pharmaceutical and biotechnology landscape. The enterprise-level funding suggests a strategic focus on scaling operations and solidifying its competitive advantage in the specialized CRO market.
See full Rapid Novor company page
